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WHO DEFINES “HEALTHY”? ETHICAL DILEMMAS 
ACROSS COMPETING INTEREST GROUPS ON GENETIC 
MANIPULATION AND GENE PATENTS 
Haley Guion* 
I. INTRODUCTION 
Genetic manipulation has led to significant advancements in the 
field of medicine and continues to hold a great deal of potential.  The term 
“genome” refers to the total array of genes in a particular individual.  The 
human genome contains approximately 25,000 genes within its 
3,000,000,000 base pairs of DNA, which form the 46 chromosomes found 
in a human cell.1  Genomic medicine is an emerging area of medicine that 
involves the use of genomic information about an individual as a part of 
their clinical care.2  Scientists employ gene therapy techniques to treat dis-
eases in an individual patient by administering genetic material (DNA) 
rather than a drug.3  This kind of genetic manipulation is developing at a 
remarkable pace, due largely to the efforts of the Human Genome Project.   
The Human Genome Project, formed in October 1990,4 is proof that the 
use of genetic manipulation to develop medicine is growing. The Human 
Genome Project sets out to sequence the human genome and “map” all of 
the human genes to the twenty-three pairs of chromosomes that exist in 
each cell, excluding sperm and egg cells.5  The organizations responsible 
for the efforts and administration of the Human Genome Project’s activi-
ties in the U.S. include the National Human Genome Research Institute of 
the National Institute of Health and the United States Department of En-
                                                           
* DePaul University College of Law, J.D. Candidate 2015.  Thank you to my family. 
1 Genome Definition, MERRIAM-WEBSTER DICTIONARY (2014), available at http://www.merriam-
webster.com/dictionary/genome. 
2 NHGRI Definition of “Genomic Medicine,” National Human Genome Research Institute (2012) at 
http://www.genome.gov/pages/About/NACHGR/Sept2012AgendaDocuments/Genomic_Medicine_Definiti
on_080112_RChisolm.pdf. 
3 Nathan A. Adams, IV, Creating Clones, Kids & Chimera: Liberal Democratic Compromise at the Cross-
roads, 17 NOTRE DAME J.L. ETHICS & PUB POL’Y 71, 71 (2003). 
4 About NHGRI: A Brief History and Timeline (2014), available at 
http://www.genome.gov/10001763#1988. 
5 CARL H. COLEMAN, ET. AL., THE ETHICS AND REGULATION OF RESEARCH WITH HUMAN 
SUBJECTS, 697 (2005). 
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ergy.  In addition, the Human Genome Project has also benefited from re-
search conducted in Britain, France, Germany, Japan, China, and Canada.6  
It has nine research branches,7 each comprised of investigators who study 
the functions within the human genome.  For example, the Cancer Genet-
ics and Comparative Genomics Branch seeks to identify genes that con-
tribute to cancer susceptibility and progression.8  By 2020, it has been pre-
dicted that the Human Genome Project will release new gene-based 
“designer drugs” for diabetes, hypertension, and mental illness into the 
market.9  The manipulation of the human genome for the purpose of de-
veloping medicine to treat disease holds a great deal of promise for adults 
and children living with certain illnesses.  As these efforts advance, there 
is a growing need for a regulatory regime over genetic manipulation that 
acknowledges its ties to ethical issues. 
With the potential that gene therapy research and development 
holds in the field of medicine comes significant ethical dilemmas about the 
definition of “illness.”  An illness to one person may be, to another, the 
cause of an engaging personality trait or rare talent; the qualities of a 
healthy baby to one parent could be the same qualities that trigger another 
mother’s decision to receive an abortion.  According to Merriam-Webster, 
illness is “a condition of being unhealthy in your body or mind” and “a 
specific condition that prevents your body or mind from working nor-
mally; sickness or disease.”10  How unhealthy do these “conditions” have 
to be to warrant a cure?  What does it meant to have a body or mind that is 
not working “normally”?  To compare, Merriam-Webster defines healthy 
as “enjoying health and vigor of body, mind, or spirit.”11  Again, one indi-
vidual’s source of enjoyment could be the same source of another’s pain.  
In order to consider the ethical dilemmas that arise from genetic 
manipulation, one must understand the groups who are interested in its 
regulation.  To begin, Part II identifies the varying opinions of government 
agencies, states, the Supreme Court, patent attorneys, bioethicists and 
scholars about its regulation.  Part III then outlines concerns about how the 
role of genetic manipulation could change the nature and norms of prenatal 
                                                           
6 National Human Genome Research Institute, at http://www.genome.gov/25019925.  
7 NHGRI Research Branches (2014), available at http://www.genome.gov/10000010. 
8 NHGRI Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Insti-
tute (2014), available at http://www.genome.gov/10000012. 
9 Francis S. Collins, Victor A. McKusick, & Krin Jegalian, Implications of the Genome Project for Medical 
Science, JAMA (Feb. 7 2001), available at http://jama.jamanetwork.com/article.aspx?articleid=193524. 
10 Illness Definition, MERRIAM-WEBSTER DICTIONARY (2014), available at http://www.merriam-
webster.com/dictionary/illness. 
11 Healthy Definition, MERRIAM-WEBSTER DICTIONARY (2014), available at http://www.merriam-
webster.com/dictionary/healthy. 
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testing and mental illness.  It describes the Supreme Court’s recent deci-
sion regarding the patent eligibility of non-naturally occurring material in 
Association of Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 
(2013), also referred to as “Myriad V”.  Part IV introduces two different 
societies and how each could regulate genetic manipulation and suggests a 
regime rooted in a traditional society.  Lastly, Part V predicts the ethical 
dilemmas that will arise with respect to genetic manipulation in mental ill-
ness and prenatal diagnosis and calls for attention to how to resolve these 
dilemmas. 
 
II. GENETIC MANIPULATION AND GENE PATENTS 
 
A. Interest Groups 
 
The viewpoints on the regulation of genetic manipulation and the 
patent eligibility of human genetic processes fall on a spectrum.  In Myriad 
V, the Court ruled that subject matter that is itself an abstract idea, natural 
phenomenon or law of nature is not patent eligible.12  Thus, at present, the 
law forbids patenting a human genetic process that is naturally occurring.  
In this case, Myriad’s patents on BRCA1 and BRCA2, genetic processes 
associated with detecting breast cancer and colon cancer13 were invalid as 
“products of nature.”14  The Court denied Myriad’s request for patents on 
the processes involving these genes, holding that the genetic material is 
patent ineligible because it is naturally occurring.15 The invention at issue 
in Myriad V is an isolated gene.  Myriad Genetics, Inc. and, in part, the 
University of Utah Research Foundation, patented the genetic processes, 
and the primary issue in the case was whether or not the processes are pat-
ent eligible, given that they use a naturally occurring segment of DNA.  In 
Myriad V, the U.S. Supreme Court granted Association for Molecular Pa-
thology’s petition for certiorari exclusively on the question, “Are human 
genes patentable?”16  In a 9-0 decision, the Supreme Court held that a 
naturally occurring DNA segment is a product of nature and not patent eli-
gible merely because it has been isolated, and, conversely, that cDNA is 
patent eligible because it is not naturally occurring.17  Justice Thomas writ-
                                                           
12 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111 (2013). 
13 Id. at 2109 
14 Id. 
15 Id. at 2111 
16 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 133 S. Ct. 2107 (U.S. 2012) (Myriad 
V). 
17 Supra note 12 at 2120. 
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ing for the majority explained that “genes and the information they encode 
are not patent eligible under §101 of the U.S. Patent Act simply because 
they have been isolated from surrounding genetic material.”18 The Court 
labeled the notion that Myriad did not “create or alter any of the genetic 
information encoded in the BRCA1 and BRCA2 genes” an “undisputed 
fact.”19 Justice Thomas reasoned: 
“The location and order of the nucleotides existed in nature before 
Myriad found them.  Nor did Myriad create or alter the genetic 
structure of DNA.  Instead, Myriad’s principal contribution was 
uncovering the precise location and genetic sequence of the 
BRCA1 and BRCA2 genes within chromosomes 17 and 13.  The 
question is whether this renders the genes patentable.”20 
Medical researchers believe the decision to make naturally occurring genes 
patent ineligible will inhibit medical research.21  Dr. Michael Crichton dis-
agrees.  in the introduction to his 2006 novel Next, he writes, “Stop patent-
ing genes.”22   Patent lawyers argue that the Court has gotten “off track” in 
its patent eligibility jurisprudence; that the naturally occurring exception is 
“inconsistent with both the statute and constitutional plan for the U.S. pat-
ent system.”23  From the perspective of patent law attorneys, Myriad V 
marked “yet another [instance] in a series of recent decisions by the Su-
preme Court that identifies the dividing line between patent-eligible and 
patent ineligible subject matter.”24  The decision places subject matter that 
is fundamental to scientific and technological work outside the domain of 
patent protection.25 
Others believe the Court’s approach to genetic patents places an 
unnecessary limit to genetic research and does not contribute meaningfully 
                                                           
18  Supra note 12 at 2120. 
19 Id. at 2116. 
20 Id. 
21 See Robert D. Truog, Will ethical requirements bring critical care research to a halt? 31 INTENSIVE 
CARE MED. 338, Issue 3 (March 2005), who believes that if current trends continue, within several years it 
could become nearly impossible to conduct research in critical care medicine.  See generally Robert Cook-
Deegan, “Gene Patents,” in From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Brief-
ing Book for Journalists, Policymakers, and Campaigns, ed. Mary Crowley 69-72 (2008), 
22 MICHAEL CRICHTON, NEXT, (Harper Collins 2006).  See also, Michael Crichton, Patenting Life, N.Y. 
TIMES, February 13, 2007, available at http://www.nytimes.com/2007/02/13/opinion/13crichton.html?_r=0  
23 Garth Janke, An Appeal to Reason Post-Myriad and Mayo – to Follow the Statute and the Constitutional 
Plan for the U.S. Patent System When Deciding Questions of Patent Eligibility, available at 
http://about.bloomberglaw.com/practitioner-contributions/an-appeal-to-reason-post-myriad-and-mayo-to-
follow-the-statute-and-the-constitutional-plan-for-the-u-s-patent-system-when-deciding-questions-of-
patent-eligibility/  
24 Charles R. Macedo, David Goldberg, U.S. Supreme Court Addresses Patent Eligibility of Isolated DNA 
and cDNA in Myriad V, Journal of Intellectual Property Law & Practice, available at 
http://www.arelaw.com/publications/view/092913myriadv/ 
25 Id. 
17#3_GUION.DOC (DO NOT DELETE) 2/5/15 5:50 PM 
2015]   WHO DEFINES “HEALTHY”?           51 
to the protection of human subjects.26  It is unlikely the result of Myriad V 
will delay discovery of genetic techniques that could save lives from ter-
minal illness, such as cancer.  The barrier of patent ineligibility to certain 
genetic manipulation techniques will have little effect on the discovery of 
treatment processes that could cure cancer.  In February 2014, the National 
Institutes of Health announced its progress in the Cancer Genome Atlas, 
which was implemented in 2005 to “speed up the identification of cancer 
genes.”27  As the tests and treatments expand the options for treatment of 
particular illnesses, the patent system will make them increasingly com-
mercialized. 
Proof that patent protection maximizes the quantity of favorable 
products is an empirical question that is very difficult to test.28  It has been 
put forth that the claim of commercial rights to a gene therapy technique is 
not the only driving force behind genetic research. 
Justice Kennedy explained the Court’s role in addressing this di-
lemma of placing limits on genetic research for the sake of protection at 
the expense of medical advancements.  He stated, “I’m sure that there are 
substantial arguments in the amicus brief that this investment [in BRCA1 
and BRCA2 patents] is necessary and that makes sense. But I certainly 
don’t think we can decide the case on that ground.”29  The Court recog-
nized in its decision that “. . . patent protection strikes a delicate balance 
between creating ‘incentives that lead to creation, invention, and discov-
ery’ and ‘impeding the flow of information that might …spur inven-
tion.’”30  Simply put, the opinion reads, “. . . Myriad did not create any-
thing. . .  it found an important and useful gene, but separating that gene 
from surrounding genetic material is not an act of invention.”31  Failure to 
create this carve out in the patent system for naturally-occurring material 
would, in fact, be “at odds with the very point of patents, which exist to 
                                                           
26 David Ozonoff, Just When You Thought It Was Safe, An Update on the Risks of Recombinant DNA Tech-
nology, 472; See also, Jeanne C. Fromer, Patent Disclosure, 94 IOWA L. REV. 539, 547 arguing for the 
“well-accepted principle” that the principle goal of the American patent system is to stimulate innovation 
(Feb. 2009). 
27 Carl Zimmer, A Catalog of Cancer Genes That’s Done, or Just A Start, N.Y. TIMES, (Feb. 6, 2014), 
available at http://www.nytimes.com/2014/02/07/science/a-catalog-of-cancer-genes-thats-done-or-just-a-
start.html?hpw&rref=science&_r=0. 
28 See M.A. Heller & R.S. Eisenberg, Can Patents Deter Innovation? The Anticommons in Biomedical Re-
search, 280 SCIENCE 698, (1998); See also R.S. Eisenberg, Patents and the Progress of Science: Exclusive 
Rights and Experimental Use, 56 U. CHI. L. REV.  1017, 1031 (1993). 
29 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013) oral argument ¶15, 
available at http://www.supremecourt.gov/oral_arguments/argument_transcripts/12-398-amc7.pdf 
30 Myriad, 133 S. Ct. at 2116 quoting Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. 
Ct. 1289 (2012).  
31 Id. at 2117 
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promote creation.”32  Justice Scalia did point out that the Supreme Court 
might not be suited to rule on legal issues about patent eligibility of human 
genetic material, concurring in part on the basis that he could not affirm 
his knowledge of the fine details of molecular biology.33 
Some have faith that, although the potential for abuse exists, the 
value of future medical advancements from genetic manipulation out-
weighs any risks of abuse.  “Genomic medicine holds the ultimate promise 
of revolutionizing the diagnosis and treatment of many illnesses.  Potential 
misuses of genetic information . . . will need to be dealt with swiftly and 
effectively.”34  The Executive Branch also carries the same faith.  An Ex-
ecutive Order issued on March 9, 2009, by President Barack Obama 
served to “remove [prior Presidential actions that limited] scientific in-
quiry, to expand NIH support for the exploration of human stem cell re-
search, and in so doing to enhance the contribution of America’s scientists 
to important new discoveries and new therapies for the benefit of human-
kind.”35 
State statutes on genetic manipulation fall all over the spectrum. 
Massachusetts’ law prohibits its residents from creating an embryo with 
the sole intent of donating the embryo for research.36  By contrast, Califor-
nia law gives authority to an advisory committee, comprised of nine mem-
bers, including at least one representative from the areas of medicine, re-
ligion, biotechnology, genetics, law, and from the general public, as well 
as at least three independent bioethicists that reflect a representative range 
of religious and ethical perspectives in California regarding the issues of 
human biotechnology.37  This committee advises the Legislature and the 
Governor on issues relating to human biotechnology.38   
Regulations by federal agencies fall in an area on the spectrum that 
appreciates a balancing test, but these agencies likely seek policies that 
give its interests the most weight.  A 2003 report by the Federal Trade 
Commission recommended a proper balance be struck between competi-
tion, law, and policy in the patent system.  “Competition and patents stand 
out among the federal policies that influence innovation.  Both competition 
and patent policy can foster innovation, but each requires a proper balance 
                                                           
32 133 S. Ct. at 2116. 
33 Id. at 2120 
34 Supra note 9.  
35 Executive Order 13505, Removing Barriers to Responsible Scientific Research Involving Human Stem 
Cells (Mar. 9, 2009), available at http://www.whitehouse.gov/the_press_office/Removing-Barriers-to-
Responsible-Scientific-Research-Involving-Human-Stem-Cells/. 
36 105 CMR 960.005. 
37 Cal. Health & Saf. Code § 24186(a)(1)-(3). 
38 Cal. Health & Saf. Code § 24186(a)(1). 
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with the other to do so.”39  The FTC looks to policies through the lens of 
how they affect innovation. By comparison, the Food and Drug Admini-
stration’s Center for Biologics Evaluation and Research (“CBR”) regulates 
human gene therapy products and uses the Public Health Service Act and 
the Federal Food Drug and Cosmetic Act as enabling statutes for over-
sight.40  The role of this agency is to oversee clinical studies to ensure 
compliance with these Acts and give scientific and regulatory advice to 
medical researchers and manufacturers in the area of novel product devel-
opment,41 a role quite different from that of the FTC.  A final example is 
the Recombinant DNA Advisory Committee of the National Institutes of 
Health, a panel of up to twenty-one national experts representing various 
fields of science, medicine, genetics, ethics, and patient perspectives that 
considers the current state of knowledge and technology regarding gene 
therapy research.42  Again, the role of this federal agency is quite distinct 
from the other two.  The decision-making process of this agency relies on 
a unique set of expert opinions with diverse viewpoints. 
It is evident that opinions differ on how to strike a balance between 
creation and regulation with respect to human genetic manipulation.  Go-
ing forward, this divide raises concerns about the ethical treatment of cer-
tain illnesses. 
 
III. CONCERNS ABOUT GENETIC MANIPULATION 
 
 Because of the differing opinions on how genetic manipulation 
should function in society, the moral compass that guides decisions by in-
terest groups on ethical issues in this area is inconsistent, if not entirely ab-
sent.  When the definition of “illness” diverges among these groups, indi-
viduals with a certain genetic makeup are vulnerable.  Individuals who are 
particularly vulnerable are those involved in prenatal testing and those 
who have mental illness.  Because of this current lack of ethical considera-
tion for these individuals, certain manipulation and prenatal testing of 
chromosomal disorders and hereditary diseases should be limited and ex-
cluded from the patent system. 
                                                           
39 FED. TRADE COMM’N, TO PROMOTE INNOVATION: THE PROPER BALANCE OF COMPETITION AND PATENT 
LAW AND POLICY, (2003), available at http://www.ftc.gov/sites/default/files/documents/reports/promote-
innovation-proper-balance-competition-and-patent-law-and-policy/innovationrpt.pdf. 
40 Cellular & Gene Therapy Products (2013), available at 
http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm.  
41 Id. 
42 National Institutes of Health, Office of Biotechnology Activities, Frequently Asked Questions about the 
NIH Review Process for Human Gene Transfer Trials (Apr. 2013), available at 
http://osp.od.nih.gov/sites/default/files/NIH_Review_Process_HGT.pdf. 
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A. Prenatal Testing and Mental Illness 
 
Today, genetic testing is available for more than 2,000 rare and 
common conditions in over 500 laboratories.43  The tests include: diagnos-
tic testing, a process used to identify a genetic condition that is making or 
in the future will make a person ill; predictive and pre-symptomatic ge-
netic testing, which find genetic variations that increase a person’s chances 
of developing specific diseases; pharmogenetic testing, which reveals in-
formation about how certain medicines are processed in a person’s body  . 
. . and prenatal testing, a test available during pregnancy to identify certain 
diseases in fetuses.44  These genetic tests involve gene therapy, which is 
the replacement of a defective or malfunctioning gene.45 
Physicians perform genetic testing of a fetus, also known as prena-
tal testing, through amniocentesis.  The test involves the withdrawal of a 
small amount of amniotic fluid that surrounds the fetus from the uterus.46  
The fetal cells are then examined for any hereditary diseases, including 
Tay-Sachs disease, spina bifida, and Down syndrome.47  The process is 
capable of detecting chromosomal disorders.48  The rates of discovery are 
high.  In a 1992 study, among the 760 women and adolescents who chose 
amniocentesis, 20 cases of fetal Down’s syndrome were detected, along 
with 7 other chromosomal disorders.49 Before 1984, prenatal screening for 
Down’s syndrome was restricted to solely asking a pregnant woman her 
age.50  She could have the procedure if she was 35 years or older.51   The 
rationale behind this limit was based upon a “well-documented trend of an 
increasing risk of Down’s syndrome in fetuses as maternal age in-
creased.”52  Then, the accessibility to the screening expanded to include 
women under 35 when medical trials and subsequent reports discovered a 
new technique that could improve the detection rate of Down’s syndrome 
in fetuses in women younger than 35.53 
                                                           
43 National Institute of Health, Genetic Testing: How it is Used for Health Care, at 
http://www.report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=43&key=G.  
44 Id. 
45 BONNIE F. FREMGEN,  PH.D.,  MEDICAL LAW & ETHICS, 173 (2002). 
46 Id. at 204 
47 Id. 
48 James E. Haddow et al., Prenatal Screening for Down’s Syndrome With Use of Maternal Serum Markers, 
327 N. ENG. J. MED. 588 (Aug. 27 1992). 
49 Id. at 590. 
50 Id. at 588. 
51 Id. 
52 Id. citing E.B. hook, Down’s syndrome: frequency in human population and factors pertinent to variation 
in rates. 
53 Id. The technique in the reports refers to maternal serum alpha-fetoprotein concentrated at midtrimester.  
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The concern here is the treatment of those fetuses whose genetic 
makeup includes one or more of chromosomal disorders.  A newly discov-
ered chromosomal disorder is not, to some, a disorder in the non-scientific 
sense of the word.  As gene transfer techniques develop, and should regu-
lations on it fail to materialize, researchers will detect more of these 
“chromosomal disorders,” disorders that may be, to some, better left un-
discoverable.  To make available to pregnant mothers the ability to learn of 
a fetus’ predisposition for a disorder or hereditary disease opens the door 
the robbing of society’s complexity.  Those who suffer from certain men-
tal illness offer value to society that, if eliminated from prenatal testing, 
would be devastating. 
Mental illness permeates the minds of individuals around the 
world.  In the United States, research shows that approximately one in four 
adults–61.5 million Americans–experiences mental illness in a given 
year.54  One in seventeen–13.6 million–lives with a serious mental illness, 
such as schizophrenia, major depression, or bipolar disorder.55  It has been 
estimated that one in seven Americans will experience a major depressive 
episode in their lifetime.56  With the sheer volume of humans affected by 
mental illness, any medical treatment of it must be handled with care. 
In 2010, a medical journal published a report that stated research-
ers at New York-Presbyterian Hospital were able to reverse depression-
like behavior in mice with therapy techniques using human and animal 
genes.  That the therapy technique used human genes means that the appli-
cation of this gene therapy to reversing depression-like symptoms could be 
successful in humans.57  Research genetic testing helps scientists learn 
about how genes contribute to health and disease and develop gene-based 
treatments in response to these findings.58  Such testing gives rise to the 
possibility of what Kay Jamison, Professor of Psychiatry at Johns Hopkins 
Medical School, who also serves on the National Advisory committee for 
Human Genome Research, predicted in 1993.59 After conducting numer-
ous studies on the connection between creativity and the artistic tempera-
                                                           
54 National Alliance on Mental Illness. Mental Illness Facts and Numbers (Mar. 2013), available at 
http://www.nami.org/factsheets/mentalillness_factsheet.pdf 
55 Id. 
56 National Healthcare Disparities Report, 2010, Chapter 2: Effectiveness of Mental Health and Substance 
Abuse, available at http://www.ahrq.gov/research/findings/nhqrdr/nhdr10/Chap2b.html  
57 Brian Alexander, et. al., Reversal of Depressed Behaviors by p11 Gene Therapy in the Nucleus Accum-
bens, 2 Sci. Transl. Med. 54; see also http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026098/  
58 Supra note 29. 
59 Kay Redfield Jamison, Touched With Fire: Manic Depression Illness and the Artistic Temperament, 253 
(Free Press 1993).  She predicted that prenatal testing for manic-depressive illness and abortion based on a 
determination that a fetus is at risk for the disease may be available before the end of the century. 
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ment in writers, artists, and poets,60 Jamison concludes that while the deci-
sion to abort a fetus with manic-depressive illness a “particularly problem-
atic” decision, she underscores that the disease is treatable, fairly common 
and the symptoms of the disease vary in severity.61  Leon R. Kass, M.D., 
Ph.D, has expressed arguments against abortions on the basis of prenatal 
test results and is also worth noting.  The following excerpt illustrates the 
difficulty of the debate: 
I have failed to provide myself with a satisfactory intellectual and 
moral justification for the practice of genetic abortion . . . Perhaps 
the pragmatists can persuade me that we should abandon the 
search for principled justification, that if we just trust people’s sit-
uational decisions or their gut reactions, everything will turn out 
fine.  Maybe they are right.  But we should not forget the sage ob-
servation of Bertrand Russell: ‘Pragmatism is like a warm bath that 
heats up so imperceptibly that you don’t know when to scream.’ 
Before we submerge ourselves irrevocably in amniotic fluid, we 
should note its connection to our own baths, into which we have 
started the hot water running.62 
 
B. cDNA Patents 
 
Another issue that accompanies the concern of the availability of 
prenatal genetic testing is the patent eligibility of such prenatal tests and 
genetic techniques, specifically in the form of cDNA patents.  In 1985, le-
gal scholar John Robertson stated, “Gene manipulation is potentially a 
very potent and very precise tool.  We need to proceed with deliberate 
care, as we largely have proceeded, until we have a clearer sense of its 
dangers and benefits.”63  His prediction that gene manipulation could be a 
“precise tool” has been realized, as private firms and universities continue 
to strive to obtain rights to human genetic processes in order to patent 
medical advancements.  A 2013 study shows that more than 4,000 genes, 
20% of human genes, have been patented in the United States.64 
                                                           
60 See generally Kay Redfield Jamison, Touched With Fire: Manic Depression Illness and the Artistic Tem-
perament, Chapter 3: Could It Be Madness–This?, (Free Press 1993) 
61 Supra note 57. 
62 L.R. Kass, Toward a More Natural Science: Biology and Human Affairs, 98 (New York Free Press, 
1988). 
63 John A. Robertson, Genetic Alteration of Embryos: The Ethical Issues, in GENETICS AND THE LAW III 
115, 125 (Aubrey Milunsky & George J. Annas eds., 1985). 
64 Stefan Lovgren, One-Fifth of Human Genes Have Been Patented, Study Reveals, NATIONAL 
GEOGRAPHIC NEWS (Oct. 13, 2005), at 
http://news.nationalgeographic.com/news/2005/10/1013_051013_gene_patent.html.  
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In order to patent a human gene, researchers are subject to 35 
U.S.C. §101.  “Whoever invents or discovers any new and useful process, 
machine, manufacture or composition of matter, or any new and useful 
improvement thereof, may obtain a patent therefore, subject to the condi-
tions and requirements of this title.”65  A patent gives the patent holder the 
right to exclude others from making, using, selling, or importing an inven-
tion for a period of time, usually twenty years.66   On June 14, 2014, the 
Supreme Court clarified how this statute relates to the patent eligibility of 
human genes and genetic processes. 
In Myriad V, the Court, in addition to its ruling that naturally-
occurring genes are patent ineligible, it also ruled that complementary 
DNA, or cDNA, from the human genome is patent eligible because such 
genetic material is not naturally occurring.67  The blanket approval of all 
non-naturally occurring genetic material as patent eligible is worrisome.  
The Court has approved of the patent eligibility of these processes, and 
their commercialization, without knowing what they are, what they do, 
what they eliminate, what they produce, and how they affect the health of 
humankind. In his noteworthy observation of the function of the legal sys-
tem, professor and philosopher Terrance McConnell argues that, “in our 
society, if behavior is not legally prohibited, then presumably people will 
not be forcibly prevented from engaging in such conduct.  To that limited 
extent, legally permitted behavior has society’s stamp of approval.”68  The 
Court has given a blind stamp of approval. 
Researchers in Myriad V modified the genetic makeup of people 
by replacing a mutated gene that causes disease with a healthy copy of the 
gene, inactivating an improperly functioning mutated gene, or introducing 
a new gene into the body to help fight the disease.69  The goal of gene 
transfer research is to cure the disease by modifying the genetic informa-
tion of the person’s cells.70  The Court in Myriad V reasoned, “the lab 
technician unquestionably creates something new when cDNA is made” 
because, “it is distinct from the DNA from which it was derived” and, “is 
                                                           
65 35 U.S.C. §101 (2012). 
66 Robert Cook-Deegan, Gene Patents, in FROM BIRTH TO DEATH AND BENCH TO CLINIC: THE HASTINGS 
CENTER BIOETHICS BRIEFING BOOK FOR JOURNALISTS, POLICYMAKERS, AND CAMPAIGNS at 69 (Mary 
Crowley ed., 2008). available at 
http://ww.w.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/gene%20patents%20chapter.
pdf . 
67 Supra note 12 at 2109. 
68 TERRANCE MCCONNELL, INALIENABLE RIGHTS: THE LIMITS OF CONSENT IN MEDICINE AND THE LAW, 
83 (Oxford University Press 2000). 
69  Gene Therapy Handbook, Genetics Home Reference, at 
http://ghr.nlm.nih.gov/handbook/therapy?show=all. 
70 Id.  
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not a product of nature.”71 With respect to cDNA patents, the concern is 
how one decides the incentives that will guide interest groups during the 
course of their manipulation over non-naturally occurring DNA.  What 
will be the ethical check on commercializing genetic material, despite the 
fact that it has been isolated?  Health law professionals, medical providers, 
and genetic researchers must carefully consider these issues, challenge 
each other and answer them, keeping in mind the unique value of every 
human life. 
 
IV. A CALL FOR A REGULATORY REGIME ROOTED IN 
A TRADITIONAL SOCIETY MODEL 
 
 The desire for immediate results from genetic manipulation has 
begun to corrode ethical considerations. The Court’s decision in Myriad V 
has provided a long overdue pause in the realm of human genetic manipu-
lation and given all interest groups reason to address its ethical concerns.  
Moving forward, technology as powerful as genetic manipulation should 
be regulated with a regime that encourages caution among researchers, 
promotes active involvement from bioethicists, respects the human ge-
nome and acknowledges the potential for irreparable harm to human kind. 
 Philosopher Stephen Toulmin distinguishes between two kinds of 
societies, which can serve as a framework for how one may decide to 
regulate genetic manipulation.  When one considers the hopes and expec-
tations around which people have structured their lives in different cultures 
and societies and at different stages in history, Toulmin argues it is possi-
ble to recognize a spectrum of inherited forms of life and standard operat-
ing procedures.  The societies range from attitudes prevalent in highly tra-
ditional societies at one extreme and so deliberately modernizing ones at 
the other.72 
 In traditional societies, life is structured around idées reçus, or “the 
conventional wisdom.”73  For those living in these societies, what ought to 
be done about any problem is equated with what is done.  The traditional 
society functions based on fixed techniques and procedures.74  By contrast, 
in modernizing societies, people continually ask how the same needs 
                                                           
71 Gene Therapy Handbook, supra. 
72 Stephen Toulmin, Technological Progress and Social Policy: The Broader Significance of Medical Mis-
haps, in Mark Siegler et al., eds., Medical Innovation and Bad Outcomes: Legal, Social, and Ethical Re-
sponses (Ann Arbor: Health Administration Press, 1987), 24. 
73  Id. 
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might be met “more efficaciously, economically, and elegantly.”75  The 
modernizing society is subject to continual refinement.76 
 Based on the history of American medicine, Toulmin argues that 
current medical practices in the United States is expected to align more 
closely with the progressive than to the traditional ideal.77  The public ex-
pects physicians to continually refine and improve their techniques and re-
searchers to develop new and more effective medical treatments.  The pos-
sibility of “a revolutionary new treatment” is never far from the minds of 
patients and doctors.78  In modernized societies, medical experimentation 
is accepted as an indispensable activity and provides the best way of im-
proving current techniques in medicine.79  Moreover, once experimenta-
tion has demonstrated effective and reasonably safe new procedures in any 
field, there is public support for putting those procedures to general use.80  
Here, one may ask, “Does society want drugs that are the result of experi-
mentation on the human genome to yield ‘reasonably safe’ procedures?”  
Surely not.  Society expects a far higher standard.  The disparity between 
the moral compasses of a traditional and a modern society illustrates how 
the different goals of interest groups would result in widely different regu-
latory regimes. 
 Moving forward, genetic manipulation should be regulated under a 
traditional society model.  Interest groups tied to the manipulation and re-
search of human genes should resist Toulmin’s theory that the United 
States is expected to align with a modernizing society.  The future of ge-
netic technologies, by their very nature, will challenge the human com-
plexity inherent in a unique and well-balanced society.  Regulations that 
emulate the goals of a traditional society will prevent what Toulmin refers 
to as “the unavoidable price to be paid for maintaining the socially desired 
momentum of medical advance.”81 
A brief look at how other countries regulate genetic manipulation 
and gene patents indicates a lean towards a traditional society model.  In 
both Japan and New Zealand, the most acceptable type of genetic manipu-
lation is of plants and the least acceptable is in humans.82  New Zealand 
                                                           
75 Stephen Toulmin, supra. 
76 Id. 
77 Supra note 72. 
78 Id. at 25. 
79  Id. 
80  Id. at 29. 
81 Id. at 34. 
82 Darryl R. J. Macer, Biotechnology and Bioethics: What is Ethical Biology? 12 MODERN 
BIOTECHNOLOGY: LEGAL, ECONOMIC AND SOCIAL DIMENSIONS, 115, TABLE 2: Reasons given for Unac-
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recently proposed a bill entitled “GE Free New Zealand,”83 which pushes 
against patenting the human genome.  A German study of university stu-
dents and professors asked the subjects the major reasons cited for the un-
acceptability of genetic manipulation.  The study placed the reasons in the 
following five categories: (1) Unnatural, playing God, unethical, feeling; 
(2) disaster, fear of unknown, ecological and environmental effects; (3) 
human misuse, insufficient controls, eugenics, cloning, humanity changed; 
(4) health effects, mutations; (5) not stated.84  Interestingly, although 42% 
of the public considers gene therapy morally wrong, Section 101 of the 
U.S. Patent Act does not include an ethical limitation on human gene ther-
apy.85   
 
V. LAW VERSUS ETHICS AND THE FUTURE OF GENETIC 
MANIPULATION 
 
Biotechnology raises moral questions that are not “simply difficult 
in the familiar sense, but are of an altogether different kind.”86  Spokes-
people for the Human Genome Project have acknowledged the public’s 
ethical concerns about genetic manipulation.  “With every new genetic 
breakthrough comes great apprehension that the information contained in 
the human genome and deciphered...will be used for ill.  The anticipated 
problems are legion and include the fear of genetic discrimination.  While 
the phrase ‘genetic discrimination’ has become ubiquitous in both popular 
and academic presses, the exact definition of the term, and the nature of 
the anticipated problem, remain unclear.”87  Medical researchers, lawmak-
ers, and others, must work together to establish a common impetus, drawn 
from an ethical theory, on genetic manipulation and use it as a moral com-
pass when ethical dilemmas arise.  
Here are two ethical theories that may offer guidance to the inter-
est groups on ways to think about genetic manipulation.  Utilitarianism, 
the most prominent consequence-based theory, accepts one and only one 
                                                                                                                                           
ceptability of Genetic Manipulation (Weinheim, Germany, 1995) available at 
http://www.eubios.info/Papers/VCH.htm (last accessed February 28, 2014). 
83 GE-Free New Zealand, available at http://www.gefree.org.nz/ (last accessed February 28, 2014). 
84 Macer, supra note 84, at 13. 
85 Id. at 21. 
86 Donald P. O’Mathúna, Bioethics and biotechnology, available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267612/  
87 Jennifer Geetter, Coding for Change: The Power of the Human Genome to Transform the American 
Health Insurance System, AM. J. L. & MED. , (March 22, 2002) at http://business.highbeam.com/42/article-
1G1-86064879/coding-change-power-human-genome-transform-american  
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basic principle of ethics: the principle of utility.88  This principle asserts 
what we ought always to produce the maximal balance of positive value 
over disvalue (or the least possible disvalue, if only undesirable results can 
be achieved).89  Rule utilitarians believe that an act’s conformity to a justi-
fied rule (that is, a rule justified by utility) makes the act and that rule is 
not expendable.90  By contrast, act utilitarians argue that observance of a 
rule (such as truth-telling) does not always maximize the general good.91  
In the context of genetic manipulation, utilitarians would favor a regula-
tory regime rooted in a traditional society model if the regime maximizes 
utility.  Utility could be a variety of things in this context.  It may be the 
utility brought from the prohibition of a gene therapy drug that, if made 
available to the public, could wipe out healthy fetuses with treatable ill-
nesses or no “illness” at all.  The traditional society model maximizes util-
ity by protecting against the elimination of valuable members of society.  
The utility maximized by this regulatory regime over genetic manipulation 
may also be the safeguards it develops against the potential for a eugenic 
society.  Philosophers, doctors, and medical ethicists argue that without 
drawing the line on the scope of research and manipulation of genetic ma-
terial, society could be deprived of its diversity.92   The fear is “those who 
have power often are so imbued with their own freedom that they disre-
member those who are disadvantaged.”93  Society that is all the same is 
certainly not a desirable society. 
A second ethical theory is Kantianism, an obligation-based the-
ory.94  A Kantian maintains that the moral worth of an individual’s action 
depends on the rule that determines the individual’s will, where the rule is 
understood as a morally valid reason that justifies the action.95   A morally 
valid reason for the rule that genetic manipulation to cure illness is not ac-
ceptable in a traditional society could be that society expects human 
makeup never be capitalized upon or exploited, but rather be respected for 
its capability to form human life. 
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89 Id. 
90 Id. 
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92 See generally W. French Anderson, M.D., Human Gene Therapy: Why Draw A Line? 14 J. MED. & 
PHILOSOPHY 681 (1989); Sarah Chan & John Harris, The Ethics of Gene Therapy, 8 MOLECULAR 
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94 Id. at 350 
95 Id. 
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The risk to the individuals involved in prenatal diagnosis and af-
fected by mental illness is becoming victims of a rapid succession of ad-
vancements in medicine, at the expense of ethical treatment to these indi-
viduals. The components that distinguish a human being as an artist, a 
writer, a composer, a musician, a director, or a world leader, lay embedded 
in their DNA.  Marc Lappe illustrates the effect that an already existing 
gene therapy technique could have on society.  He writes: 
“A case in point could be the recently uncovered loci that seem to 
flag the presence of genes that predispose carriers to manic depres-
sive illness.  Should we use the knowledge of the likely presence 
of such “deviant” genes to abort affected fetuses?  Such a program 
could conceivably reduce the genetic burden brought about by the 
presence of these genes in the human population, but it would also 
potentially deprive us of great poets like Sylvia Plath or politicians 
like Winston Churchill, each of whom suffered from bipolar manic 
depression.”96 
Myriad V keeps the powerful technology of genetic manipulation 
and subsequent patents on these techniques in check, for now.   Yet, schol-
ars believe that in evaluating policy decisions concerning the human DNA, 
“. . . the well-focused and clearly articulated financial interests of the bio-
technology industry will overcome the diffuse and difficult-to-articulate 
social and moral interests of the world’s majority,” a theory known as the 
public choice justification.97    
Seymour Lederberg, Ph. D, reminds researchers and physicians 
that “the purpose in treating genetic handicaps should be to reduce illness 
and harm to the individual.”98  This is a utilitarian approach, the utility be-
ing the maximization of health.  If interest groups can agree on what is 
“healthy,” then these groups can begin to resolve ethical dilemmas on how 
to define chromosomal disorders in the context of human health and 
whether or not genetic manipulation should come into play. 
 
VI. CONCLUSION 
 
No single solution can resolve the ethical dilemmas that will arise 
from the manipulation of the human genome.  However, society needs a 
                                                           
96 Marc Lappe, The Limits of Genetic Inquiry, 17 Hastings Center Report 5 (1987). 
97 Pilar N. Ossorio, The Human Genome As Common Heritage: Common Sense or Legal Nonsense?, 35 
J.L. MED. & ETHICS 425, 427 (2007). 
98 Seymour Lederberg, Ph. D, Governmental Responsibilities and Genetic Disease, in GENETICS AND THE 
LAW III 425, 429 (Aubry Milunski et al. 2012 ). 
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moral compass to guide interest groups on how to handle the human ge-
nome.  Competing interest groups must come to an agreement on driving 
force behind genetic manipulation and gene therapy techniques.  Pair this 
with a regulatory regime rooted in traditional societal ideals and a solution 
becomes clearer.  Is the goal of genetic manipulation to eliminate a certain 
illness?  What kind of illness?  How does one characterize this illness as 
“unhealthy”?  One must ask the same question when it comes to the goal 
of gene patents.  Does a company seek to patent a gene in order to stimu-
late innovation?  Gain recognition?  Catalyze the development of a healthy 
society?  Jones Day, the law firm that represented Myriad Genetics, re-
leased a statement saying it was pleased with Myriad V because it rein-
forces the notion that “intellectual property rights and patents drive inno-
vation.”99  Is this true?  Certainly patent law firms do not always consider 
the ethical dilemmas about genetic patents, but society may want to begin 
to expect this of them in the future.  Interest groups can only begin to re-
solve the challenge of ethical dilemmas once they recognize that society 
characterizes certain illnesses in different ways. In light of the Myriad V 
decision, health law professionals, medical researchers, and state legisla-
tors will be forced to ask questions about the ethics, regulation, and re-
sponsible manipulation of the human genome.   With so many interest 
groups seeking to get their hands on a specific piece of genetic manipula-
tion, it is nearly impossible to centralize its regulation in a common ideal.  
Now is the time to address and answer the following question: How does 
society want to define “healthy” in the context of genetic manipulation?  
Interest groups must keep in mind how far they are willing to go for re-
search and where they are willing to place limits on their powers.  Laws 
are not always moral, nor do they include ethical considerations.  In the fu-
ture, the law and ethics related to genetic manipulation and the patent eli-
gibility of certain genetic processes will undoubtedly collide.  Failure to 
recognize this imminent issue on genetic manipulation could allow for ir-
reversible harm.  Moving forward, interests groups should remember the 
famous words of Confucius: “Too many hands in the cookie jar only leads 
to crumbs for none.” 
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